These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

602 related items for PubMed ID: 20079162

  • 1. Pemetrexed monotherapy versus pemetrexed plus platinum combination as second-line treatment for advanced non-small cell lung cancer.
    Zhang YF, Chen ZW, Lu S.
    Chin Med J (Engl); 2009 Oct 20; 122(20):2472-6. PubMed ID: 20079162
    [Abstract] [Full Text] [Related]

  • 2. Pemetrexed: a multitargeted antifolate.
    Rollins KD, Lindley C.
    Clin Ther; 2005 Sep 20; 27(9):1343-82. PubMed ID: 16291410
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer.
    Sun JM, Lee KW, Kim JH, Kim YJ, Yoon HI, Lee JH, Lee CT, Lee JS.
    Jpn J Clin Oncol; 2009 Jan 20; 39(1):27-32. PubMed ID: 18952704
    [Abstract] [Full Text] [Related]

  • 4. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer.
    Smit EF, Burgers SA, Biesma B, Smit HJ, Eppinga P, Dingemans AM, Joerger M, Schellens JH, Vincent A, van Zandwijk N, Groen HJ.
    J Clin Oncol; 2009 Apr 20; 27(12):2038-45. PubMed ID: 19307503
    [Abstract] [Full Text] [Related]

  • 5. [Treatment of the unresectable non small cell lung carcinoma].
    Spásová I.
    Cas Lek Cesk; 2005 Apr 20; 144(9):602-12; discussion 612-3. PubMed ID: 16193938
    [Abstract] [Full Text] [Related]

  • 6. Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.
    Tiseo M, Giovannetti E, Tibaldi C, Camerini A, Di Costanzo F, Barbieri F, Burgers JA, Vincent A, Peters GJ, Smit EF, Ardizzoni A.
    Lung Cancer; 2012 Oct 20; 78(1):92-9. PubMed ID: 22889494
    [Abstract] [Full Text] [Related]

  • 7. The role of pemetrexed as maintenance treatment in advanced NSCLC: a Phase III randomized trial.
    Gridelli C, Di Maio M.
    Expert Opin Pharmacother; 2010 Feb 20; 11(2):321-4. PubMed ID: 20053140
    [Abstract] [Full Text] [Related]

  • 8. Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial.
    Ardizzoni A, Tiseo M, Boni L, Vincent AD, Passalacqua R, Buti S, Amoroso D, Camerini A, Labianca R, Genestreti G, Boni C, Ciuffreda L, Di Costanzo F, de Marinis F, Crinò L, Santo A, Pazzola A, Barbieri F, Zilembo N, Colantonio I, Tibaldi C, Mattioli R, Cafferata MA, Camisa R, Smit EF.
    J Clin Oncol; 2012 Dec 20; 30(36):4501-7. PubMed ID: 23109689
    [Abstract] [Full Text] [Related]

  • 9. [Comparison of treatment efficacy of the second and the third generations of chemoradiotherapy regimens containing platinum on advanced non-small cell lung cancer].
    Wang YM, Guo LJ, Li LS, Li P, Zheng J, Li L.
    Ai Zheng; 2005 Dec 20; 24(12):1514-7. PubMed ID: 16351804
    [Abstract] [Full Text] [Related]

  • 10. Survival rates and tolerability of platinum-based chemotherapy regimens for elderly patients with non-small-cell lung cancer (NSCLC).
    Costa GJ, Fernandes AL, Pereira JR, Curtis JR, Santoro IL.
    Lung Cancer; 2006 Aug 20; 53(2):171-6. PubMed ID: 16757059
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pemetrexed single agent in previously treated non-small cell lung cancer: a multi-institutional observational study.
    Bearz A, Garassino I, Cavina R, Favaretto A, Boccalon M, Talamini R, Berretta M, Spazzapan S, Simonelli C, Santoro A, Tirelli U.
    Lung Cancer; 2008 May 20; 60(2):240-5. PubMed ID: 18022729
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer.
    Ohe Y, Ichinose Y, Nakagawa K, Tamura T, Kubota K, Yamamoto N, Adachi S, Nambu Y, Fujimoto T, Nishiwaki Y, Saijo N, Fukuoka M.
    Clin Cancer Res; 2008 Jul 01; 14(13):4206-12. PubMed ID: 18594001
    [Abstract] [Full Text] [Related]

  • 14. A cost-effectiveness analysis of docetaxel versus pemetrexed in second-line chemotherapy for stage IIIb or IV non-small cell lung cancer in China.
    Yu YF, Chen ZW, Zhou Z, Song ZB, Li ZM, Jian H, Zhang YF, Lu S.
    Chemotherapy; 2010 Jul 01; 56(6):472-7. PubMed ID: 21099219
    [Abstract] [Full Text] [Related]

  • 15. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.
    Greenhalgh J, McLeod C, Bagust A, Boland A, Fleeman N, Dundar Y, Oyee J, Dickson R, Davis H, Green J, McKenna E, Pearson M.
    Health Technol Assess; 2010 Oct 01; 14(Suppl. 2):33-9. PubMed ID: 21047489
    [Abstract] [Full Text] [Related]

  • 16. A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer.
    Dittrich C, Papai-Szekely Z, Vinolas N, Sederholm C, Hartmann JT, Behringer D, Kazeem G, Desaiah D, Leschinger MI, von Pawel J.
    Eur J Cancer; 2014 Jun 01; 50(9):1571-80. PubMed ID: 24703574
    [Abstract] [Full Text] [Related]

  • 17. Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation.
    Metro G, Chiari R, Mare M, Giannarelli D, Tofanetti FR, Minotti V, Ferraldeschi M, Giuffrida D, Marcomigni L, Bennati C, Fischer MJ, Meacci M, Bellavita R, Pistola L, Ludovini V, Crinò L.
    Cancer Chemother Pharmacol; 2011 Dec 01; 68(6):1405-12. PubMed ID: 21468755
    [Abstract] [Full Text] [Related]

  • 18. [Impact of histology on efficacy of pemetrexed: pemetrexed in second-line setting and as maintenance therapy after first-line treatment in Chinese patients with advanced NSCLC].
    Zhou C, Wu Y, Sun Y, Wang Y, Wang X, Zhang X.
    Zhonghua Zhong Liu Za Zhi; 2014 Jan 01; 36(1):29-33. PubMed ID: 24685083
    [Abstract] [Full Text] [Related]

  • 19. Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902.
    Kim YH, Hirabayashi M, Togashi Y, Hirano K, Tomii K, Masago K, Kaneda T, Yoshimatsu H, Otsuka K, Mio T, Tomioka H, Suzuki Y, Mishima M.
    Cancer Chemother Pharmacol; 2012 Aug 01; 70(2):271-6. PubMed ID: 22752216
    [Abstract] [Full Text] [Related]

  • 20. Pemetrexed for previously treated patients with non-small cell lung cancer and differences in efficacy according to thymidylate synthase expression.
    Igawa S, Ryuge S, Wada M, Otani S, Maki S, Takakura A, Katono K, Sasaki J, Sato Y, Masuda N.
    Chemotherapy; 2012 Aug 01; 58(4):313-20. PubMed ID: 23147191
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.